Department of Radiology, Stanford University, Stanford, CA 94305, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Department of Radiology, Stanford University, Stanford, CA 94305, USA; Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.
Biomaterials. 2019 Jun;206:73-86. doi: 10.1016/j.biomaterials.2019.03.021. Epub 2019 Mar 20.
Catheter-based intra-arterial drug therapies have proven effective for a range of oncologic, neurologic, and cardiovascular applications. However, these procedures are limited by their invasiveness and relatively broad drug spatial distribution. The ideal technique for local pharmacotherapy would be noninvasive and would flexibly deliver a given drug to any region of the body with high spatial and temporal precision. Combining polymeric perfluorocarbon nanoemulsions with existent clinical focused ultrasound systems could in principle meet these needs, but it has not been clear whether these nanoparticles could provide the necessary drug loading, stability, and generalizability across a range of drugs, beyond a few niche applications. Here, we develop polymeric perfluorocarbon nanoemulsions into a generalized platform for ultrasound-targeted delivery of hydrophobic drugs with high potential for clinical translation. We demonstrate that a wide variety of drugs may be effectively uncaged with ultrasound using these nanoparticles, with drug loading increasing with hydrophobicity. We also set the stage for clinical translation by delineating production protocols that are scalable and yield sterile, stable, and optimized ultrasound-activated drug-loaded nanoemulsions. Finally, we exhibit a new potential application of these nanoemulsions for local control of vascular tone. This work establishes the power of polymeric perfluorocarbon nanoemulsions as a clinically-translatable platform for efficacious, noninvasive, and localized ultrasonic drug uncaging for myriad targets in the brain and body.
基于导管的动脉内药物治疗已被证明可有效用于多种肿瘤学、神经病学和心血管应用。然而,这些程序受到其侵袭性和相对广泛的药物空间分布的限制。局部药物治疗的理想技术是非侵入性的,并且可以灵活地将特定药物递送到身体的任何区域,具有高时空精度。将聚合的全氟碳纳米乳液与现有的临床聚焦超声系统相结合,原则上可以满足这些需求,但尚不清楚这些纳米颗粒是否可以提供必要的药物负载、稳定性和在多种药物中的通用性,而不仅仅是少数利基应用。在这里,我们将聚合的全氟碳纳米乳液开发成一种通用平台,用于超声靶向递送疏水性药物,具有很高的临床转化潜力。我们证明,使用这些纳米颗粒可以有效地用超声使各种药物解笼,药物负载随疏水性增加而增加。我们还通过描述可扩展的生产方案来为临床转化奠定基础,这些方案可产生无菌、稳定和优化的超声激活载药纳米乳液。最后,我们展示了这些纳米乳液在局部控制血管张力方面的新潜在应用。这项工作确立了聚合全氟碳纳米乳液作为一种临床转化平台的强大功能,可用于大脑和身体中无数靶标进行高效、非侵入性和局部超声药物解笼。